File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Outcome of Chinese children with medulloblastoma: a multi-center experience with risk-adapted therapy

TitleOutcome of Chinese children with medulloblastoma: a multi-center experience with risk-adapted therapy
Authors
Keywordschemotherapy regimen
cisplatin
child
cyclophosphamide
china
Issue Date2020
PublisherOxford University Press. The Journal's web site is located at https://academic.oup.com/neuro-oncology
Citation
The 19th International Symposium on Pediatric Neuro-Oncology (ISPNO) 2020, Karuizawa, Japan, 13-16 December 2020. In Neuro-Oncology, 2020, v. 22 n. Suppl. 3, p. iii381 How to Cite?
AbstractBACKGROUND: Medulloblastoma is the commonest brain tumor in young children but literature on Chinese is scarce. We hereby present the outcome of children with medulloblastoma managed according to a risk- and age-stratified guideline from ten institutions across China. METHODS: Patients <18 years of age diagnosed with medulloblastoma between January 2016 and April 2019 were reviewed. Patients ≥3 years, stratified into average-risk (≤1.5cm2 residual tumor, non-metastatic, non-anaplastic histology) and high-risk (others) groups, were treated with risk-adapted craniospinal irradiation (average-risk: 23.4Gy, high-risk: 36Gy), tumor boost, and chemotherapy (lomustine/cisplatin/vincristine). Patients <3 years (considered high-risk, other than patients with localized and desmoplastic/nodular histology) received chemotherapy (cyclophosphamide/vincristine, high-dose methotrexate, carboplatin/etoposide) with/without delayed irradiation. RESULTS: 112 patients were included with a median age at diagnosis of 6.5 years (range: 0.5–16.7). 16 patients (14.3%) had residual tumor >1.5cm2 and 36 (32%) had metastasis. Available data on histological subtype (n=87) were classic in 56 (64%), desmoplastic/nodular or extensive nodularity in 23 (26%), and large cell/anaplastic in 8 (9%). Molecular subgrouping (n=55) assigned tumors as WNT-activated (n=8, 15%), SHH-activated (n=17, 31%), Group 3 (n=12, 22%) and Group 4 (n=18, 33%). Respective 2-year EFS/OS for patients ≥3 and <3 years were 86.0±4.0%/96.4±2.1% and 57.8±12.6%/81.4±9.8% (EFS/OS p<0.001/p=0.009). Significant difference in outcome was also observed between patients with average-risk and high-risk disease (EFS/OS p=0.006/p=0.018). CONCLUSION: We demonstrated feasibility in protocolizing the inter-disciplinary treatment for medulloblastoma in China. This will serve as a prototype for the standardization of pediatric neuro-oncology care in the country.
DescriptionPoster presentation - LINC-15
Persistent Identifierhttp://hdl.handle.net/10722/288269
ISSN
2020 Impact Factor: 12.3
2015 SCImago Journal Rankings: 3.196

 

DC FieldValueLanguage
dc.contributor.authorSun, XF-
dc.contributor.authorLiu, APY-
dc.contributor.authorYang, Q-
dc.contributor.authorWang, J-
dc.contributor.authorWu, S-
dc.contributor.authorZhen, Z-
dc.contributor.authorWang, J-
dc.contributor.authorGuo, H-
dc.contributor.authorJiang, L-
dc.contributor.authorMa, X-
dc.contributor.authorWeng, W-
dc.contributor.authorYang, L-
dc.contributor.authorHuang, L-
dc.contributor.authorLi, J-
dc.contributor.authorChan, GCF-
dc.date.accessioned2020-10-05T12:10:23Z-
dc.date.available2020-10-05T12:10:23Z-
dc.date.issued2020-
dc.identifier.citationThe 19th International Symposium on Pediatric Neuro-Oncology (ISPNO) 2020, Karuizawa, Japan, 13-16 December 2020. In Neuro-Oncology, 2020, v. 22 n. Suppl. 3, p. iii381-
dc.identifier.issn1522-8517-
dc.identifier.urihttp://hdl.handle.net/10722/288269-
dc.descriptionPoster presentation - LINC-15-
dc.description.abstractBACKGROUND: Medulloblastoma is the commonest brain tumor in young children but literature on Chinese is scarce. We hereby present the outcome of children with medulloblastoma managed according to a risk- and age-stratified guideline from ten institutions across China. METHODS: Patients <18 years of age diagnosed with medulloblastoma between January 2016 and April 2019 were reviewed. Patients ≥3 years, stratified into average-risk (≤1.5cm2 residual tumor, non-metastatic, non-anaplastic histology) and high-risk (others) groups, were treated with risk-adapted craniospinal irradiation (average-risk: 23.4Gy, high-risk: 36Gy), tumor boost, and chemotherapy (lomustine/cisplatin/vincristine). Patients <3 years (considered high-risk, other than patients with localized and desmoplastic/nodular histology) received chemotherapy (cyclophosphamide/vincristine, high-dose methotrexate, carboplatin/etoposide) with/without delayed irradiation. RESULTS: 112 patients were included with a median age at diagnosis of 6.5 years (range: 0.5–16.7). 16 patients (14.3%) had residual tumor >1.5cm2 and 36 (32%) had metastasis. Available data on histological subtype (n=87) were classic in 56 (64%), desmoplastic/nodular or extensive nodularity in 23 (26%), and large cell/anaplastic in 8 (9%). Molecular subgrouping (n=55) assigned tumors as WNT-activated (n=8, 15%), SHH-activated (n=17, 31%), Group 3 (n=12, 22%) and Group 4 (n=18, 33%). Respective 2-year EFS/OS for patients ≥3 and <3 years were 86.0±4.0%/96.4±2.1% and 57.8±12.6%/81.4±9.8% (EFS/OS p<0.001/p=0.009). Significant difference in outcome was also observed between patients with average-risk and high-risk disease (EFS/OS p=0.006/p=0.018). CONCLUSION: We demonstrated feasibility in protocolizing the inter-disciplinary treatment for medulloblastoma in China. This will serve as a prototype for the standardization of pediatric neuro-oncology care in the country.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at https://academic.oup.com/neuro-oncology-
dc.relation.ispartofNeuro-Oncology-
dc.relation.ispartofThe 19th International Symposium on Pediatric Neuro-Oncology (ISPNO) 2020-
dc.subjectchemotherapy regimen-
dc.subjectcisplatin-
dc.subjectchild-
dc.subjectcyclophosphamide-
dc.subjectchina-
dc.titleOutcome of Chinese children with medulloblastoma: a multi-center experience with risk-adapted therapy-
dc.typeConference_Paper-
dc.identifier.emailLiu, APY: apyliu@hku.hk-
dc.identifier.emailChan, GCF: gcfchan@hku.hk-
dc.identifier.authorityLiu, APY=rp01357-
dc.identifier.authorityChan, GCF=rp00431-
dc.description.natureabstract-
dc.identifier.doi10.1093/neuonc/noaa222.450-
dc.identifier.hkuros314987-
dc.identifier.volume22-
dc.identifier.issueSuppl. 3-
dc.identifier.spageiii381-
dc.identifier.epageiii381-
dc.publisher.placeUnited States-
dc.identifier.issnl1522-8517-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats